Literature DB >> 31761352

Recent treatment progress of triple negative breast cancer.

Yang Chang-Qing1, Liu Jie1, Zhao Shi-Qi1, Zhu Kun1, Gong Zi-Qian1, Xu Ran1, Lu Hui-Meng1, Zhou Ren-Bin1, Zhao Gang2, Yin Da-Chuan3, Zhang Chen-Yan4.   

Abstract

Breast cancer (BC) is a serious worldwide disease that threatens women's health. Particularly, the morbidity of triple-negative breast cancer (TNBC) is higher than that of other BC types due to its high molecular heterogeneity, metastatic potential and poor prognosis. TNBC lacks of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), so there are still no effective treatment methods for TNBC. Here, we reviewed the classification of TNBC, its molecular mechanisms of pathogenesis, treatment methods and prognosis. Finding effective targets is critical for the treatment of TNBC. Also, refining the classification of TNBC is benefited to choose the treatment of TNBC, because the sensitivity of chemotherapy is different in different TNBC. Some new treatment methods have been proposed in recent years, such as nutritional therapy and noncoding RNA treatment methods. There are some disadvantages, such as the side effect on normal cells after nutrient deprivation, low specificity and instability of noncoding RNA. More studies are necessary to improve the treatment of TNBC.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Metastasis; Molecular mechanisms; Recurrence; Treatment methods; Triple negative breast cancer

Year:  2019        PMID: 31761352     DOI: 10.1016/j.pbiomolbio.2019.11.007

Source DB:  PubMed          Journal:  Prog Biophys Mol Biol        ISSN: 0079-6107            Impact factor:   3.667


  24 in total

Review 1.  Long Non-coding RNA ZFPM2-AS1: A Novel Biomarker in the Pathogenesis of Human Cancers.

Authors:  Gabriel B K Sasa; Cheng Xuan; Guoliang Lyu; Xianfeng Ding; Fang Meiyu
Journal:  Mol Biotechnol       Date:  2022-01-31       Impact factor: 2.695

2.  Altered Glycan Expression on Breast Cancer Cells Facilitates Infection by T3 Seroptype Oncolytic Reovirus.

Authors:  Danahe Mohammed; Melanie Koehler; Andra C Dumitru; Pavithra Aravamudhan; Danica M Sutherland; Terence S Dermody; David Alsteens
Journal:  Nano Lett       Date:  2021-11-11       Impact factor: 11.189

3.  Diabetes regulated anti-inflammatory lncRNA is overexpressed in triple-negative breast cancer and predicts chemoresistance and tumor recurrence.

Authors:  Peng Wang; Wei Peng; Jian Peng
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

Review 4.  The Emerging Role of EVA1A in Different Types of Cancers.

Authors:  Huijie Zhao; Huiyang Liu; Yihan Yang; Honggang Wang
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

Review 5.  cAMP Signaling in Cancer: A PKA-CREB and EPAC-Centric Approach.

Authors:  Muhammad Bilal Ahmed; Abdullah A A Alghamdi; Salman Ul Islam; Joon-Seok Lee; Young-Sup Lee
Journal:  Cells       Date:  2022-06-24       Impact factor: 7.666

Review 6.  Triple-negative breast cancer: A run-through of features, classification and current therapies.

Authors:  Meghana Manjunath; Bibha Choudhary
Journal:  Oncol Lett       Date:  2021-05-05       Impact factor: 2.967

7.  Icaritin enhances the efficacy of cetuximab against triple-negative breast cancer cells.

Authors:  Li Yin; Xiao-Wei Qi; Xun-Zhou Liu; Ze-Yu Yang; Rui-Li Cai; Hong-Juan Cui; Li Chen; Shi-Cang Yu
Journal:  Oncol Lett       Date:  2020-03-31       Impact factor: 2.967

8.  A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis.

Authors:  Pawat Pattarawat; Jessica T Hunt; Jacob Poloway; Collin J Archibald; Hwa-Chain Robert Wang
Journal:  Cancer Chemother Pharmacol       Date:  2021-05-27       Impact factor: 3.288

9.  17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells.

Authors:  Yu Zuo; Heng Xu; Zhifeng Chen; Fengmin Xiong; Bei Zhang; Kaixian Chen; Hualiang Jiang; Cheng Luo; Hao Zhang
Journal:  Oncol Rep       Date:  2020-03-26       Impact factor: 3.906

Review 10.  The Role of PPARγ Ligands in Breast Cancer: From Basic Research to Clinical Studies.

Authors:  Giuseppina Augimeri; Cinzia Giordano; Luca Gelsomino; Pierluigi Plastina; Ines Barone; Stefania Catalano; Sebastiano Andò; Daniela Bonofiglio
Journal:  Cancers (Basel)       Date:  2020-09-14       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.